The Mag

Genome editing, Biomining, Vaccines

In this issue:

  • Genome editing: Turning biotech upside down
  • Biomining: Europe’s new focus on bioleaching
  • Vaccines: A turbulent time for market and research
  • The biotech industry's IPO dilemma: Launch here or across the pond?
  • Interview with Emmanuelle Charpentier, one of the scientists involved in the discovery of the CRISPR/Cas9 system
  • Economy: Ongoing IPO boom for European biotechs
  • News from our partner associations European Biotechnology Network, EAPB, EDMA, DIA, BIO Deutschland and the Swiss Biotech Association
  • ... and our special "IP in Life Sciences”.